CD70 and neoplasm: ARGX-110, a human CD70-specific monoclonal antibody which is currently undergoing Phase I clinical testing, is a strong antagonist of CD70/CD27 signaling and mediates destruction of CD70-expressing tumor cells through enhanced ADCC [21].